【Health and Welfare News】 The results of the largest comparative study based on real-world clinical results (RWD real-world data) on the first-line anticancer drugs gemcitabine + nab-paclitaxel and folipyrinox for metastatic pancreatic cancer have been published.
A team of professors Park Chan-soo and Park Byeong-gyu from the Department of Gastroenterology at National Health Insurance Ilsan Hospital published a research paper analyzing the effectiveness of primary chemotherapy for patients with metastatic pancreatic cancer in the latest issue of Cancers, an international journal of oncology.
We analyzed real-world data on the treatment of metastatic pancreatic cancer using healthcare big data that combines National Health Insurance claim data and National Cancer Center National Cancer Registry data.
Health insurance claim data includes key information such as cancer patient diagnosis, treatment, and survival period, but does not provide cancer stage information. Cancer stage information can be found in the National Cancer Center’s national cancer registration data.
The research team selected domestic metastatic pancreatic cancer patients by linking National Health Insurance claim data and the National Cancer Center’s national cancer registration data through the combination of healthcare big data, which has become available since 2021.
The research team analyzed survival times by chemotherapy among 21,899 patients with metastatic pancreatic cancer in Korea from 2012 to 2019, targeting 8,652 who received chemotherapy.
As a result of the analysis, the median survival time for gemcitabine ± erlotinib treatment was 6 months, while the median survival time for gemcitabine + nab-paclitaxel was 10 months and FOLFIRINOX was 11 months. .
In particular, as a result of comparing 1,134 patients treated with gemcitabine + nab-paclitaxel and FOLFIRINOX through propensity score matching, the median survival time of the two anticancer treatments was the same, 11 months. There was no significant difference in effect.
Looking at the period, the median survival time for metastatic pancreatic cancer patients in 2012–2013 was 6 months, while it improved to 10 months in 2018–2019. It was analyzed as a result of increased use of gemcitabine + nab-paclitaxel and FOLFIRINOX since 2016 as they were covered by health insurance.
This study is the largest-scale study comparing the effectiveness of gemcitabine + nab-paclitaxel and FOLFIRINOX, the first recommended anticancer drugs for metastatic pancreatic cancer. The anticancer treatment effect proven in clinical studies is It is significant that it has been confirmed to be effective even in actual medical environments.
Professor Byeong-gyu Park, the corresponding author, said, “This study was able to derive more meaningful results by combining healthcare big data to select only patients with metastatic pancreatic cancer,” and added, “It is expected to help medical staff decide on treatment methods.” did it
